FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

Official Title

A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients With Surgically Resectable Non-Small Cell Lung Cancer


Phase 2 trial to study FL-101 alone or in combination with nivolumab in patients who have surgically resectable Non-Small Cell Lung Cancer.

Trial Description

Primary Outcome:

  • Number of patients with treatment related adverse events as assessed by NCI CTCAE v.5.0
Secondary Outcome:
  • Number of patients with treatment efficacy as assessed by pathological response (percentage of residual tumour) by independent pathology review.
  • Major Pathologic Response
  • Complete Pathologic Response
  • Objective Response Rate (ORR)
  • MRD measurement by ctDNA
A 2-Cohort, Phase 2, multicentre, parallel-design trial that will study patients with surgically resectable, stages I-IIIA, non-small cell lung cancer (NSCLC) . The clinical study will focus on whether FL-101 has direct anti-tumour activity when given alone prior to surgery, and if FL-101 improves the anti-tumour response when given in combination with nivolumab prior to surgery.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society